Six of nine patients at the highest 740 mg daily ... Roche's oral GLP-1 achieved 6.1% placebo-adjusted weight at the optimum dose in its phase 1 trial, while Viking's VK2735 – like Zepbound ...
Blujepa is the first new type of oral antibiotic to treat UTIs to gain approval in more than 20 years. Its development was ...
Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...
The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
The Oral Health BSc qualifies you to become a registered dental therapist or hygienist, working independently within dental teams to provide preventative and clinical treatments. You’ll study at Queen ...
Companies looking to compete in the GLP-1 market are adding value to the R&D spend across the pharma sector. Wedbush Securities managing director of equity research Michael Pachter joins Market ...
NEW YORK, March 19, 2025--Nuveen Credit Strategies Income Fund (NYSE: JQC) today announced that its Board of Trustees (the "Board") has approved the terms of the issuance of transferable rights ...
Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback